

this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments

In the Claims:

Please replace pending claim 82 with the following claim 82.

91 82. (Once amended) The pharmaceutical composition of claim 81, wherein the epitope consists of the amino acid sequence TTLFCASDAK (SEQ ID NO:32).

Please replace pending claim 89 with the following claim 89.

92 89. (Once amended) The diagnostic agent of claim 88, wherein the peptide consists of the amino acid sequence TTLFCASDAK (SEQ ID NO:32).

Please replace pending claim 90 with the following claim 90.

93 90. (Once amended) An isolated cytolytic T cell line which specifically recognizes a complex of an HLA-A3 molecule and a peptide epitope of about 11 amino acids having the amino acid sequence TTLFCASDAK (SEQ ID NO:32).

Please replace pending claim 93 with the following claim 93.

94

93. (Once amended) The isolated antigenic HLA-A3 binding peptide of claim 92 consisting of the amino acid sequence TTLFCASDAK (SEQ ID NO:32).

Please replace pending claim 94 with the following claim 94.

95

94. (Once amended) An isolated nucleic acid molecule consisting of a nucleotide sequence encoding the amino acid sequence TTLFCASDAK (SEQ ID NO:32).